Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.

The Journal of clinical investigation - 1 Mar 1990

Grant D M, Mörike K, Eichelbaum M, Meyer U A

Abstract excerpt

The biochemical basis underlying the genetic polymorphism of drug N-acetylation was investigated using a combination of in vivo and in vitro assays for arylamine N-acetyltransferase (NAT) activity and content in human liver. The acetylator phenotype of 26 surgical patients was determined using caffeine as an innocuous probe drug by measurement of the 5-acetyl-amino-6-formylamino-3-methyluracil to 1-methylxanthine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Acetyltransferases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Arylamine N-Acetyltransferase

Share to Phenotype

Share to Uracil

Source

Open in PubMed Open full text

Identifiers

PMID: 2312737
DOI: 10.1172/JCI114527
PMCID: PMC296518

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.PMID 2312737Read ↗

Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes.Semantic proximity Read ↗

Polymorphism of human acetyltransferases.Semantic proximity Read ↗

Polymorphisms of N-acetyltransferase genes.Semantic proximity Read ↗

Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.Semantic proximity Read ↗

Acetaminophen is an inhibitor of hepatic N-acetyltransferase 2 in vitro and in vivo.Semantic proximity Read ↗

Molecular mechanism of slow acetylation of drugs and carcinogens in humans.Semantic proximity Read ↗

Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity.Semantic proximity Read ↗

Pharmacogenetics, Regulation and Structural Properties of the Drugmetabolizing Enzymes Arylamine N-acetyltransferases.Semantic proximity Read ↗

N-acetyltransferase (NAT) 1 and NAT2 enzyme activities drive interindividual variability in sulfamethoxazole N-acetylation.Semantic proximity Read ↗

Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice.Semantic proximity Read ↗

Acetylator status, drug metabolism and disease.Semantic proximity Read ↗

Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.